Efficiency Study of Siwu Tang to Treat Brain Hypoperfusion Syndrome
Study Details
Study Description
Brief Summary
Brain hypoperfusion patients may cause vascular dementia results from their hypoperfusion state except that is a risk factor for stroke. The most common clinical symptom of hypoperfusion syndrome is dizziness.Siwu tang is made of Angelica sinensis (Oliv.) Diels (當歸), Rehmannia glutinosa (Gaertn) Libosch (熟地黃), Paeonia lactiflora Pall (白芍), Ligusticum chuanxiong Hort (川芎), and that was used to treat patients with blood deficiency for several centuries. the purpose of the present study was to investigate the complementary effect of siwu tang on brain hypoperfusion syndrome patients
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
We designed a randomized, double-blinded controlled study, and a total of 80 patients with brain hypoperfusion syndrome should be finished assessment in two years. The 80 patients with hypoperfusion syndrome were divided into as follows:1) control group, receiving siwu tang placebo 3 g bid continuously two weeks except ordinary treatment; 2) treatment group, receiving siwu tang 3 g bid continuously two weeks except ordinary treatment. The patients were assessed before, and 4 weeks (weeks±3 days) and 12 weeks (12 weeks±3 days) after siwu tang treatment, respectively. Primary outcome measure was cerebral blood flow by using single photon emission computed tomography (SPECT); Second outcome measure included severity of dizziness by using visual analogue scale (VAS); cognitive function by using Mini-Mental Status (MMSE), Cognitive Abilities Screening Instrument (CASI), and Clinical Dementia Rating (CDR); quality of life by using barthel index (BI) and Functional Independent Measure (FIM).
We predict that siwu tang can improve cerebral blood flow, and clinical manifestation including dizziness, and cognition function and quality of life in patients with brain hypoperfusion syndrome .
Study Design
Outcome Measures
Primary Outcome Measures
- cerebral blood flow [12 weeks after treatment]
Primary outcome measure was cerebral blood flow by using single photon emission computed tomography (SPECT)
Secondary Outcome Measures
- severity of dizziness [12 weeks after treatment]
severity of dizziness by using visual analogue scale (VAS)
- cognitive function [12 weeks after treatment]
cognitive function by using Mini-Mental Status (MMSE), Cognitive Abilities Screening Instrument (CASI), and Clinical Dementia Rating (CDR)
- quality of life [12 weeks after treatment]
quality of life by using barthel index (BI) and Functional Independent Measure (FIM)
Eligibility Criteria
Criteria
Inclusion Criteria:
-
age between 18y/o to 80 y/o and had brain hypoperfusion syndrome such as dizziness
-
barthel index (BI) > 60。
-
single photon emission computer tomography(SPECT) or MRI exam show hypoperfusion area
Exclusion Criteria:
- Patient had cancer or uremia,liver cirrhosis
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | China Medical University Hospital | Taichung | Taiwan | 404 |
Sponsors and Collaborators
- China Medical University Hospital
Investigators
- Study Director: Chun-Chung Chen, master, China Medical University Hospital
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- DMR98-IRB-282